Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Portosystemic Encephalopathy Clear all
Withdrawn Phase 3 Interventional

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

NCT02086825
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jul 22, 2026, 11:57 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

NCT05071716
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin SSD, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
139
States / cities
Dothan, Alabama • Chandler, Arizona • Peoria, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jul 22, 2026, 11:57 AM EDT
Recruiting Not applicable Interventional

Affect of Melatonin on Sleep and Cognition in Cirrhosis

NCT07046429
View directory record Official record
Conditions
Hepatic Encephalopathy, Covert Hepatic Encephalopathy, Cirrhosis, Sleep Disturbances and Insomnia
Interventions
Melatonin tablet 3 mg once daily, Thiamine
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jul 22, 2026, 11:57 AM EDT
Completed Not applicable Interventional

Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents

NCT04315571
View directory record Official record
Conditions
Hypertension, Portal, Ascites
Interventions
Gore® Viatorr® Endoprosthesis with controlled expansion, Large Volume Paracentesis with albumin infusion
Device · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 11:57 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease

NCT04940416
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Neurofit (oculometric testing)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jul 22, 2026, 11:57 AM EDT
Completed Phase 1 Interventional

Fecal Transplant in Recurrent Hepatic Encephalopathy

NCT02636647
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Fecal transplant
Biological
Lead sponsor
Jasmohan Bajaj
Federal
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jul 22, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

NCT03515044
View directory record Official record
Conditions
Overt Hepatic Encephalopathy
Interventions
40 mg Rifaximin SSD once daily, 40 mg Rifaximin SSD twice daily, 80 mg Rifaximin SSD once daily, 80 mg Rifaximin SSD twice daily, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
34
States / cities
Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Jul 22, 2026, 11:57 AM EDT
Completed Not applicable Interventional

Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration

NCT05526404
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Dieta mobile application
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 22, 2026, 11:57 AM EDT
Completed Phase 4 Interventional Results available

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Jul 22, 2026, 11:57 AM EDT
Terminated Phase 2 Interventional

Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy

NCT04155099
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
RBX7455, Placebo
Biological
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jefferson, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Jul 22, 2026, 11:57 AM EDT
Not listed Not applicable Interventional

Timing of Acute Palliative Care Consultation in Critically Ill Patients

NCT02858778
View directory record Official record
Conditions
Multiple Organ Failure, End Stage Cardiac Failure, End Stage Chronic Obstructive Airways Disease, Chronic Kidney Disease Stage 5, Hepatic Encephalopathy, Sepsis, Dementia, Multiple Sclerosis, Parkinson's Disease, In-Hospital Cardiac Arrest, Solid Organ Cancer
Interventions
Early order of palliative care consultation
Other
Lead sponsor
Wayne State University
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Jul 22, 2026, 11:57 AM EDT
Completed Not applicable Interventional

Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial

NCT03493204
View directory record Official record
Conditions
Hepatic Encephalopathy, Ascites, Liver Diseases, Cirrhosis
Interventions
Meal delivery, Standard pamphlet with Dietary Advice
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jul 22, 2026, 11:57 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy

NCT00558038
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
AST-120, lactulose
Drug
Lead sponsor
Ocera Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Jul 22, 2026, 11:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

FMT in Cirrhosis and Hepatic Encephalopathy

NCT03796598
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Fecal Microbial transplant Capsules, Fecal Microbial Transplant Enema, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jul 22, 2026, 11:57 AM EDT
Terminated Phase 2 Interventional Results available

Study of Lactulose in Children With Chronic Liver Disease

NCT00811434
View directory record Official record
Conditions
Minimal Hepatic Encephalopathy
Interventions
Lactulose, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Jul 22, 2026, 11:57 AM EDT
Terminated Phase 3 Interventional Results available

RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial

NCT00364689
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, Lactulose, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jul 22, 2026, 11:57 AM EDT
Terminated Phase 2 Interventional

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

NCT06987968
View directory record Official record
Conditions
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Interventions
VS-01 on top of SOC (Active Treatment Group), SOC
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 22, 2026, 11:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Trial to Improve Quality of Life in People With Cirrhosis

NCT05061992
View directory record Official record
Conditions
Cirrhosis
Interventions
Lactulose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Jul 22, 2026, 11:57 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

NCT01846663
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Placebo, Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Jul 22, 2026, 11:57 AM EDT
Completed Not applicable Interventional

Effect of Brief Dietary Intervention on Ammonia Levels

NCT05376488
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
One meal
Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jul 22, 2026, 11:57 AM EDT
Not yet recruiting No phase listed Observational

Revealing Engagement Patterns Among Hepatic Encephalopathy Patients

NCT06201988
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Jul 22, 2026, 11:57 AM EDT
Completed No phase listed Observational

TIPS Plus Transvenous Obliteration for Gastric Varices

NCT04044248
View directory record Official record
Conditions
Cirrhosis, Liver, Hypertension, Portal, Esophageal and Gastric Varices, Bleeding Gastric, Encephalopathy
Interventions
TIPS-obliteration
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
8 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 22, 2026, 11:57 AM EDT
Completed Phase 2 Interventional Results available

VE303 for Treatment of Hepatic Encephalopathy (HE)

NCT04899115
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Placebo, VE303, oral vancomycin
Drug
Lead sponsor
Patricia Bloom
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jul 22, 2026, 11:57 AM EDT
Recruiting Phase 2 Interventional

Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement

NCT06052176
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Albumin Infusion
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 11:57 AM EDT